EXEL · Company research
Exelixis Inc (EXEL): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
26records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| 2 Under-the-Radar Stocks to Buy and Hold | The article recommends two underrated biotech stocks: Axsome Therapeutics, which is experiencing strong growth with its drug Auvelity (51% YoY sales growth) and has a promising pipeline including potential new indications; and Exelixis, a cancer-focused biotech with a dominant drug Cabometyx protected until at least 2030, plus encouraging progress on pipeline candidates like zanzalintinib. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.667 | 1 |
| 2 Under-the-Radar Stocks to Buy and Hold | The article recommends two underrated biotech stocks: Axsome Therapeutics, which is experiencing strong growth with its drug Auvelity (51% YoY sales growth) and has a promising pipeline including potential new indications; and Exelixis, a cancer-focused biotech with a dominant drug Cabometyx protected until at least 2030, plus encouraging progress on pipeline candidates like zanzalintinib. | View source ↗ | The Motley Fool | Oct 16, 2026 | bullish | 0.667 | 1 |
| Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term | Exelixis (EXEL), an oncology-focused biotechnology company, is highlighted as a stock to watch with a Zacks Rank #3 (Hold) and VGM Score of A. The company demonstrates strong growth potential with a Growth Style Score of A and forecasted year-over-year earnings growth of 15.9% for the current fiscal year, supported by recent upward analyst revisions. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term | Exelixis (EXEL), an oncology-focused biotechnology company, is highlighted as a stock to watch with a Zacks Rank #3 (Hold) and VGM Score of A. The company demonstrates strong growth potential with a Growth Style Score of A and forecasted year-over-year earnings growth of 15.9% for the current fiscal year, supported by recent upward analyst revisions. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again | Exelixis (EXEL), a biomedical and genetics drug developer, has demonstrated a consistent pattern of beating earnings estimates over the last two quarters with an average surprise of 10.91%. The company's positive Earnings ESP of +2.44% combined with its Zacks Rank #3 (Hold) rating suggests another potential earnings beat is likely, as stocks with this combination historically beat consensus estimates nearly 70% of the time. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again | Exelixis (EXEL), a biomedical and genetics drug developer, has demonstrated a consistent pattern of beating earnings estimates over the last two quarters with an average surprise of 10.91%. The company's positive Earnings ESP of +2.44% combined with its Zacks Rank #3 (Hold) rating suggests another potential earnings beat is likely, as stocks with this combination historically beat consensus estimates nearly 70% of the time. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance | Exelixis, Inc. (EXEL) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Exelixis Inc. Common Stock (EXEL) Company Profile - Pluang | Exelixis Inc. Common Stock (EXEL) Company Profile Pluang | View source ↗ | Pluang | Oct 14, 2026 | neutral | 0 | 0.6 |
| Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance Singapore | Exelixis, Inc. (EXEL) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 14, 2026 | neutral | 0 | 0.6 |
| Exelixis, Inc. (EXEL) Latest Stock News & Headlines - Yahoo Finance | Exelixis, Inc. (EXEL) Latest Stock News & Headlines Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| Exelixis (NasdaqGS:EXEL) Stock Forecast & Analyst Predictions - Simply Wall Street | Exelixis (NasdaqGS:EXEL) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 13, 2026 | neutral | 0 | 0.6 |
| Exelixis, Inc. (EXEL) Stock Price, News, Quote & History - Yahoo! Finance Canada | Exelixis, Inc. (EXEL) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| EXEL Stock Fundamentals & Key Ratios - Pluang | EXEL Stock Fundamentals & Key Ratios Pluang | View source ↗ | Pluang | Oct 9, 2026 | neutral | 0 | 0.6 |
| Exelixis, Inc. - Simply Wall Street | Exelixis, Inc. Simply Wall Street | View source ↗ | Simply Wall Street | Oct 8, 2026 | neutral | 0 | 0.6 |
| Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus? - Yahoo Finance | Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Exelixis, Inc. (EXEL) Stock Forecasts - Yahoo Finance | Exelixis, Inc. (EXEL) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Is Exelixis Stock Engineered To Make You Money? - Trefis | Is Exelixis Stock Engineered To Make You Money? Trefis | View source ↗ | Trefis | Oct 7, 2026 | neutral | 0 | 0.6 |
| Exelixis (EXEL) Stock May Be Undervalued As Earnings Stay In Focus - Yahoo Finance | Exelixis (EXEL) Stock May Be Undervalued As Earnings Stay In Focus Yahoo Finance | View source ↗ | Yahoo Finance | Oct 7, 2026 | neutral | 0 | 0.6 |
| Exelixis, Inc. (EXEL) Stock forecasts - Yahoo Finance UK | Exelixis, Inc. (EXEL) Stock forecasts Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 5, 2026 | neutral | 0 | 0.6 |
| EXEL: Exelixis Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits | EXEL: Exelixis Inc Latest Stock Price, Analysis, News and Trading Ideas Stocktwits | View source ↗ | Stocktwits | Sep 30, 2026 | neutral | 0 | 0.6 |
| Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans? - TradingView | Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans? TradingView | View source ↗ | TradingView | Sep 24, 2026 | neutral | 0 | 0.6 |
| Exelixis (NASDAQ:EXEL): A Value Stock Backed by Strong Fundamentals - ChartMill | Exelixis (NASDAQ:EXEL): A Value Stock Backed by Strong Fundamentals ChartMill | View source ↗ | ChartMill | Aug 22, 2026 | neutral | 0 | 0.6 |
| Exelixis (EXEL) Stock Drops As Guidance Cut Clouds Profit Strength - Simply Wall Street | Exelixis (EXEL) Stock Drops As Guidance Cut Clouds Profit Strength Simply Wall Street | View source ↗ | Simply Wall Street | Aug 6, 2026 | neutral | 0 | 0.6 |
| Exelixis (EXEL) Is Down 6.7% After Cutting 2026 Revenue Outlook Amid Oncology Investment Pivot - Yahoo Finance | Exelixis (EXEL) Is Down 6.7% After Cutting 2026 Revenue Outlook Amid Oncology Investment Pivot Yahoo Finance | View source ↗ | Yahoo Finance | Aug 6, 2026 | neutral | 0 | 0.6 |
| EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth? - Yahoo Finance | EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 9, 2026 | neutral | 0 | 0.6 |
| EXELIXIS, INC. ($EXEL) CEO 2025 Pay Revealed | EXEL Stock News - Quiver Quantitative | EXELIXIS, INC. ($EXEL) CEO 2025 Pay Revealed | EXEL Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Apr 15, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.